* patients in 9 who progression class * patients with exclusion criteria to the corimuno-19 cohort. * hypersensitivity to bevacizumab or to any of their excipients. * pregnancy * active cancer with undergoing treatment * oxygen patient requiring long-term oxygen before hospitalization * patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator. * contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery. * hypersensitivity to the active substance or one of the excipients

* patients in 9 who progression class * patients with exclusion criteria to the corimuno-19 cohort. * hypersensitivity to bevacizumab or to any of their excipients. * pregnancy * active cancer with undergoing treatment * oxygen patient requiring long-term oxygen before hospitalization * patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator. * contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery. * hypersensitivity to the active substance or one of the excipients

- patients in 9 who progression class - patients with exclusion criteria to the corimuno-19 cohort. - hypersensitivity to bevacizumab or to any of their excipients. - pregnancy - active cancer with undergoing treatment - oxygen patient requiring long-term oxygen before hospitalization - patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator. - contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery. - hypersensitivity to the active substance or one of the excipients

- patients in 9 who progression class - patients with exclusion criteria to the corimuno-19 cohort. - hypersensitivity to bevacizumab or to any of their excipients. - pregnancy - active cancer with undergoing treatment - oxygen patient requiring long-term oxygen before hospitalization - patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator. - contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery. - hypersensitivity to the active substance or one of the excipients